Dyne Therapeutics Appoints Wildon Farwell, M.D., MPH, as Chief Medical Officer
March 04 2021 - 7:25AM
Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company
focused on advancing innovative life-transforming therapeutics for
people living with genetically driven diseases, today announced the
appointment of Wildon Farwell, M.D., MPH, as chief medical officer.
Dr. Farwell brings expertise in clinical development and medical
affairs in neuromuscular diseases and oligonucleotide therapies.
“Wildon brings tremendous clinical experience
and has played a leading role in the development of multiple
oligonucleotide therapies, including one approved for a rare
neuromuscular disease,” said Joshua Brumm, president and chief
executive officer of Dyne. “He will be instrumental in engaging
with global regulatory agencies, key clinicians, investigators and
patient communities. Wildon’s appointment further strengthens
Dyne’s clinical and medical expertise as we advance our three
programs toward the clinic and exemplifies our commitment to
building the world’s leading muscle disease company.”
Dr. Farwell joins Dyne from Biogen, Inc., where
he was vice president, global head of neuromuscular diseases,
medical affairs. During his 10 years at Biogen, Dr. Farwell led the
development and life cycle management of SPINRAZA® (nusinersen), an
oligonucleotide and the first therapy approved for the treatment of
spinal muscular atrophy. He also led the late-stage development of
tofersen, an investigational oligonucleotide therapy for
amyotrophic lateral sclerosis, oversaw clinical and biomarker
development for Biogen’s neuromuscular disease portfolio, and began
his tenure at the company leading pharmacovigilance for multiple
product candidates. Previously, Dr. Farwell was an Assistant
Professor in Medicine at Harvard Medical School and a physician at
Brigham and Women’s Hospital and the VA Boston Healthcare System.
He received his M.D. from the University of Missouri School of
Medicine and an MPH in clinical effectiveness from Harvard
University School of Public Health.
“I’ve seen firsthand the profound impact that
new therapies for diseases with few or no treatment options can
have on patients, and Dyne has an exciting opportunity to make a
difference for people living with rare muscle diseases,” said Dr.
Farwell. “I’m thrilled to be a part of a company leading a
differentiated approach to delivering therapeutics to muscle and to
join at an important time when we are laser focused on progressing
our DM1, DMD and FSHD programs to clinical trials.”
About Dyne Therapeutics
Dyne Therapeutics is building a leading muscle
disease company dedicated to advancing innovative life-transforming
therapeutics for people living with genetically driven
diseases. With its proprietary FORCE™ platform, Dyne is
developing modern oligonucleotide therapeutics that are designed
to overcome limitations in delivery to muscle tissue seen with
other approaches. Dyne’s broad portfolio of therapeutic
candidates for serious muscle diseases includes programs for
myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy
(DMD) and facioscapulohumeral muscular dystrophy (FSHD). For more
information, please visit https://www.dyne-tx.com/, and follow
us on Twitter, LinkedIn and Facebook.
Forward-Looking Statements
This press release contains forward-looking
statements that involve substantial risks and uncertainties. All
statements, other than statements of historical facts,
contained in this press release, including statements regarding
Dyne’s strategy, future operations, prospects, plans and objectives
constitute forward-looking statements within the meaning of
The Private Securities Litigation Reform Act of 1995. The words
“anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,”
“intend,” “may,” “might,” “objective,” “ongoing,” “plan,”
“predict,” “project,” “potential,” “should,” or “would,” or the
negative of these terms, or other comparable terminology are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Dyne
may not actually achieve the plans, intentions or expectations
disclosed in these forward-looking statements, and you should not
place undue reliance on these forward-looking statements.
Actual results or events could differ materially from the plans,
intentions and expectations disclosed in these
forward-looking statements as a result of various important
factors, including: uncertainties inherent in the identification
and development of product candidates, including the conduct
of research activities and the initiation and completion of
preclinical studies and clinical trials; uncertainties as to the
availability and timing of results from preclinical studies
and clinical trials; the timing of and Dyne’s ability to submit
investigational new drug applications; whether results
from preclinical studies will be predictive of the results of
later preclinical studies and clinical trials; whether Dyne’s cash
resources will be sufficient to fund the Company’s foreseeable
and unforeseeable operating expenses and capital expenditure
requirements for the anticipated periods; the impact of the
COVID-19 pandemic on Dyne’s business and operations; as well
as the risks and uncertainties identified in Dyne’s filings with
the Securities and Exchange Commission (SEC), including the
Company’s Annual Report on Form 10-K for the year ended December
31, 2020 and in subsequent filings Dyne may make with the SEC. In
addition, the forward-looking statements included in this
press release represent Dyne’s views as of the date of this
press release. Dyne anticipates that subsequent events and
developments will cause its views to change. However, while
Dyne may elect to update these forward-looking statements at some
point in the future, it specifically disclaims any obligation to
do so. These forward-looking statements should not be relied
upon as representing Dyne’s views as of any date subsequent to the
date of this press release.Contact:
Dyne TherapeuticsAmy Reillyareilly@dyne-tx.com
857-341-1203
Dyne Therapeutics (NASDAQ:DYN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Dyne Therapeutics (NASDAQ:DYN)
Historical Stock Chart
From Jul 2023 to Jul 2024